MBX Biosciences annual return on equity
2024
2025
MBX Biosciences Return on Equity (ROE) Growth & History (MBX)
MBX Biosciences's return on equity was −27.76% for fiscal 2025.
View full MBX Biosciences company overviewMBX Biosciences annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −27.76% | +39.20 pp |
| 2024 | 2024-12-31 | −66.95% | — |
MBX Biosciences quarterly return on equity
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −8.76% | −0.22 pp |
| Q1 2026 | 2026-03-31 | −5.83% | +3.86 pp |
| Q4 2025 | 2025-12-31 | −5.83% | +0.06 pp |
| Q3 2025 | 2025-09-30 | −7.13% | +11.12 pp |
| Q2 2025 | 2025-06-30 | −8.54% | — |
| Q1 2025 | 2025-03-31 | −9.69% | — |
| Q4 2024 | 2024-12-31 | −5.89% | — |
| Q3 2024 | 2024-09-30 | −18.24% | — |
MBX Biosciences return on equity trends
Between the periods ended 2024-12-31 and 2025-12-31, MBX Biosciences's return on equity increased from −66.95% to −27.76%, a change of +39.20 percentage points. The latest reported quarter, Q2 2026, shows −8.76%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review MBX Biosciences source filings ↗